Arrowhead Pharmaceuticals (ARWR) Long-Term Investments (2010 - 2023)

Arrowhead Pharmaceuticals (ARWR) has 12 years of Long-Term Investments data on file, last reported at $42.8 million in Q2 2023.

• Quarterly Long-Term Investments fell 74.2% year-over-year to $42.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $42.8 million (down 74.2% YoY) and the FY2022 annual result came in at $105.9 million, down 56.89% from the prior year.
• Long-Term Investments retreated to $42.8 million in Q2 2023, from $78.8 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $245.6 million in Q3 2021 to a low of $26.3 million in Q4 2019.
• A 5-year average of $122.9 million and a median of $113.3 million in 2020 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2020 — Long-Term Investments soared 321.04% — and 2023, when it plunged 74.2%.
• Tracing ARWR's Long-Term Investments over 5 years: stood at $26.3 million in 2019, then soared by 321.04% to $110.9 million in 2020, then jumped by 96.27% to $217.6 million in 2021, then sank by 46.78% to $115.8 million in 2022, then plunged by 63.04% to $42.8 million in 2023.
• The last three Long-Term Investments figures came in at $42.8 million (Q2 2023), $78.8 million (Q1 2023), and $115.8 million (Q4 2022), per Business Quant data.